Uutiset-näyttösivun murupolku en
The #MedSafetyWeek campaign between 3 and 9 November 2025 promotes drug safety
Fimea is participating in the international #MedSafetyWeek campaign celebrating its 10th anniversary from 3 to 9 November 2025. The campaign encourages people to report suspected adverse reactions associated with the use of medicines and, consequently, to promote drug safety.
This year, the campaign theme is ‘We can all help make medicines safer’, which emphasises the role of medicine users, healthcare professionals, authorities and pharmaceutical companies in the promotion of drug safety.
Uppsala Monitoring Center (UMC), an international foundation operating under the auspices of the World Health Organisation, coordinates the campaign that this year brings together a record number of 130 organisations and 117 countries throughout the global campaign week in over 60 languages.
The campaign can be seen across Fimea’s social media channels on LinkedIn and Bluesky. Participate in the campaign by sharing the posts with people in your networks using the tag #MedSafetyWeek.
Adverse reaction records provide more information about drug safety
In Finland, healthcare professionals and consumers can report suspected adverse drug and vaccine reactions to Fimea. An adverse reaction means a harmful and unintended response to a drug.
Submitting a report of an adverse reaction is not a substitute for a consultation with the relevant healthcare provider to determine whether treatment or medication is required.
The primary purpose of the adverse reaction reporting system is to help identify unknown and rare adverse drug reactions. As such, Fimea would like to receive reports especially on adverse reactions that are not mentioned in the medicine’s package leaflet.
Regulatory authorities and pharmaceutical companies collect information on adverse drug reactions worldwide, gradually increasing the knowledge on the safety of a particular drug. Authorities are particularly interested in adverse reactions of new drugs, serious adverse reactions and new, previously unknown adverse reactions.
Campaign website (UMC)
More information on monitoring the safety of medicines, adverse reactions and reporting them on Fimea’s website (For public):
Monitoring the safety of medicinal products
Adverse reactions